



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic




PRODUCT INFORMATION

Angiotensin I (human, rat, mouse) (trifluoroacetate salt)

Item No. 24737

Formal Name:	5-L-isoleucine-angiotensin I, trifluoroacetate salt
MF:	C ₆₂ H ₈₉ N ₁₇ O ₁₄ • XCF ₃ COOH
FW:	1,296.5
Purity:	≥95%
Supplied as:	A lyophilized powder
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Angiotensin I (human, rat, mouse) (trifluoroacetate salt) is supplied as a lyophilized powder. A stock solution may be made by dissolving the angiotensin I (human, rat, mouse) (trifluoroacetate salt) in water. The solubility of angiotensin I (human, rat, mouse) (trifluoroacetate salt) in water is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Angiotensin I is an endogenous peptide that is converted to the vasoconstrictor angiotensin II (Item No. 17150) by angiotensin-converting enzyme (ACE).¹ It binds to angiotensin receptors in human myometrium membrane preparations ($K_d = 11.2$ nM) and increases renal vascular resistance in isolated rat kidney ($EC_{50} = 10.5$ nM).^{2,3} *In vivo*, angiotensin I (5 µg/kg, i.c.v.) increases mean arterial pressure (MAP) and plasma arginine vasopressin (AVP) level in fetal ewes.⁴

References

- Chen, Z., Tan, F., Erdös, E.G., et al. Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors. *Hypertension* **46**(6), 1368-1373 (2005).
- Bouley, R., Pérodin, J., Plante, H., et al. N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor. *Eur. J. Pharmacol.* **343**(2-3), 323-331 (1998).
- Schmidt, M., Giesen-Grouse, E.-M., Krieger, J.-P., et al. Effect of angiotensin converting enzyme inhibitors on the vasoconstrictor action of angiotensin I on isolated rat kidney. *J. Cardiovasc. Pharmacol.* **8**(suppl 10), S100-S105 (1986).
- Shi, L., Mao, C., Zeng, F., et al. Central angiotensin I increases fetal AVP neuron activity and pressor responses. *Am. J. Physiol. Endocrinol. Metab.* **298**(6), E1274-E1282 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.